Screener
Immix Biopharma, Inc. IMMX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Loss from operations | (10,803,855) | (4,682,925) |
| Other income (expense): | ||
| Interest income | 717,168 | 150,219 |
| Total other income (expense), net | 717,168 | 150,219 |
| Loss before provision for income taxes | (10,086,687) | (4,532,706) |
| Provision for income taxes | - | 9,822 |
| Net loss | (10,086,687) | (4,542,528) |
| Other comprehensive income: |
Document
FAQ
- What is Immix Biopharma, Inc.'s other income (expense)?
- Immix Biopharma, Inc. (IMMX) reported other income (expense) of $717.17K in Q1 2026.
- How has Immix Biopharma, Inc.'s other income (expense) changed year-over-year?
- Immix Biopharma, Inc.'s other income (expense) increased by 377.4% year-over-year, from $150.22K to $717.17K.
- What is the long-term trend for Immix Biopharma, Inc.'s other income (expense)?
- Over 3 years (2021 to 2025), Immix Biopharma, Inc.'s other income (expense) has grown at a -71.1% compound annual growth rate (CAGR), from -$23.1M to $555.53K.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Immix Biopharma, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude